HLA DQA1*05 (rs2097432) testing for anti-TNF biological therapy

Test covered by the reimbursement:

YES

Gender:

Woman/Man

Material:

Peripheral blood, Buccal swab …

Turnover time:

3 weeks

STATIM:

1 week

Material:

Peripheral blood | 1x 3 ml of whole blood in K3 EDTA tube

Storage after examination: week after the report is issued 2 – 8°C

Buccal swab | 2x swab stick for buccal swab collection

Storage after examination: week after the report is issued 2 – 8°C

Isolated DNA from blood | 10–100 ng/μL of isolated DNA from blood in a PCR tube of at least 15 μL.

Storage after examination: stored in a DNA archive without restriction 15°C

Quick test description:

Detection of rs2097432 (HLA DQA1*05 allele) by real-time PCR diagnostic kit.

Test details:

The HLA-DQA1*05A>G (rs2097432) allele variant is associated with a significantly higher incidence and faster progression of the formation of anti-TNF antibodies. Up to 91% of patients develop antibodies within one year of treatment. This genetic testing may help with the personalised selection of anti-TNF therapy and the need to combine it with immunomodulators that reduce the risk of antibody formation in carriers of the HLA-DQA1*05A>G (rs2097432) allele when compared to wild genotype patients. Approximately 79% of antidrug antibody (ADA) patients are reported to carry the HLA-DQA1*05A>G (rs2097432) allele. The remaining 21% of patients produce these antibodies without carrying this allele.
The test detects the HLA-DQA1*05 allele by real-time PCR. In case of positive findings, genotyping of variant rs2097432 by Sanger sequencing follows.

back to list